FIELD: biotechnologies.
SUBSTANCE: invention refers to a biotechnology industry, and namely to synthetic peptides having a non-narcotic type of analgetic action of a general formula: 1 H - XDL - L-Leu - D-His - L-Lys - L-Leu - L-Gln - L-Thr - R2 (I), where: H - hydrogen, XDL - absence of amino acid or L-Tyr, R2 - OMe or NH2, as well as peptides - retroinversions of formula (I), which have reverse sequence of amino acids with replacement of L-shape of amino acids with D-shape and D-shape of amino acids with L-shape, with the following general formula: 2 H - D-Thr - D-Gln - D-Leu - D-Lys - L-His - D-Leu - XDL1 - R2 (II), where: H - hydrogen, XDL1 - absence of amino acid or D-Tyr, R2 - OMe or NH2.
EFFECT: invention allows producing safe analgetic medical preparations with a non-narcotic type of analgetic action.
5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SPECIFIC PEPTIDE CLATHRIN INHIBITORS | 2017 |
|
RU2651491C1 |
| FAMILY OF PEPTIDES POSSESSING ANALGESIC ACTIVITY | 2005 |
|
RU2286169C1 |
| PEPTIDE ANTAGONISTS OF CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE | 2017 |
|
RU2742826C2 |
| PEPTIDE ANTAGONISTS OF PEPTIDE HORMONES FROM THE CALCITONIN GROUP (CALCITONIN GENE-RELATED PEPTIDES (CGRP)) AND THEIR APPLICATION | 2013 |
|
RU2624016C2 |
| PROTECTED CALCITONINE PEPTIDES | 2000 |
|
RU2193567C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| PRODRUG COMPOSITIONS WITH HIGH DEGREE OF PENETRATION BASED ON PEPTIDES AND RELATED COMPOUNDS | 2010 |
|
RU2627065C2 |
| PEPTIDE ANALOGUES GH-RH WITH OPPOSING ACTION, WAY OF DEPRESSION OF GH LEVEL, WAY OF DEPRESSION OF IGF-INIGF-II LEVEL, APPLICATION FOR INHIBITION OF GROWTH OF CANCER CELLS, PHARMACOLOGICALLY ACCEPTABLE COMPOSITION (VARIANTS) | 2004 |
|
RU2335506C2 |
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| PEPTIDE DERIVATIVES - ANALOGS OF GRF OR THEIR NONTOXIC SALTS | 1990 |
|
RU2096416C1 |
